Entinostat
- Generic Name
- Entinostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20N4O3
- CAS Number
- 209783-80-2
- Unique Ingredient Identifier
- 1ZNY4FKK9H
- Background
Entinostat is under investigation for the treatment and other of Volunteers, Breast Cancer, Human Volunteers, and Normal Volunteers. Entinostat has been investigated for the treatment of Non-Small Lung Cancer, Epigenetic Therapy.
- Indication
联合芳香化酶抑制剂用于治疗激素受体（HR）阳性、人类表皮生长因子受体-2（HER-2）阴性，经内分泌治疗复发或进展的局部晚期或转移性乳腺癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT02909452
- Locations
- 🇺🇸
The START Center for Cancer Care, San Antonio, Texas, United States
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT02897778
- Locations
- 🇺🇸
The START Center for Cancer Care, San Antonio, Texas, United States
Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Taizhou EOC Pharma Co., Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT02833155
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy Medical Sciences, Beijing, Beijing, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-07-01
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 61
- Registration Number
- NCT02820961
- Locations
- 🇺🇸
Sarah Cannon Research Institute HealthONE, Denver, Colorado, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
- Conditions
- Brain Stem NeoplasmPineal Region NeoplasmRecurrent LymphomaRecurrent Malignant Solid NeoplasmRecurrent Primary Central Nervous System NeoplasmRecurrent Visual Pathway GliomaRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Primary Central Nervous System NeoplasmRefractory Visual Pathway Glioma
- Interventions
- First Posted Date
- 2016-05-24
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT02780804
- Locations
- 🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
- First Posted Date
- 2016-03-15
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 89
- Registration Number
- NCT02708680
- Locations
- 🇺🇸
Ft. Wayne Hematology and Oncology, Fort Wayne, Indiana, United States
🇺🇸St. Jude Medical Center, Fullerton, California, United States
🇺🇸Saint Barnabas Medical Cancer Center, Livingston, New Jersey, United States
Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Vastra Gotaland Region
- Target Recruit Count
- 29
- Registration Number
- NCT02697630
- Locations
- 🇸🇪
Department of oncology, Sahlgrenska University Hospital, Gothenburg, Västra Götaland Region, Sweden
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 57
- Registration Number
- NCT02453620
- Locations
- 🇺🇸
Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 196
- Registration Number
- NCT02437136
- Locations
- 🇺🇸
Dana Farber Cancer Institution, Boston, Massachusetts, United States
🇺🇸The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer
- First Posted Date
- 2014-04-16
- Last Posted Date
- 2014-10-08
- Lead Sponsor
- Syndax Pharmaceuticals
- Registration Number
- NCT02115594
- Locations
- 🇺🇸
Tennessee Oncololgy, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.